51. Adult mouse astrocytes degrade amyloid-β in vitro and in situ
- Author
-
Fengrong Yan, Samuel C. Silverstein, Roman Anankov, Thomas C. Brionne, Emily Lu, Tony Wyss-Coray, Jens Husemann, and John D. Loike
- Subjects
Chemokine ,Pathology ,medicine.medical_specialty ,Amyloid beta ,General Biochemistry, Genetics and Molecular Biology ,Pathogenesis ,Mice ,Alzheimer Disease ,Cell Movement ,mental disorders ,medicine ,Animals ,Chemokine CCL2 ,Amyloid beta-Peptides ,biology ,Monocyte ,Neurodegeneration ,Chemotaxis ,General Medicine ,medicine.disease ,Peptide Fragments ,In vitro ,nervous system diseases ,Cell biology ,medicine.anatomical_structure ,Astrocytes ,biology.protein ,Alzheimer's disease - Abstract
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by excessive deposition of amyloid-beta (Abeta) peptides in the brain. One of the earliest neuropathological changes in AD is the accumulation of astrocytes at sites of Abeta deposition, but the cause or significance of this cellular response is unclear. Here we show that cultured adult mouse astrocytes migrate in response to monocyte chemoattractant protein-1 (MCP-1), a chemokine present in AD lesions, and cease migration upon interaction with immobilized Abeta(1-42). We also show that astrocytes bind and degrade Abeta(1-42). Astrocytes plated on Abeta-laden brain sections from a mouse model of AD associate with the Abeta deposits and reduce overall Abeta levels in these sections. Our results suggest a novel mechanism for the accumulation of astrocytes around Abeta deposits, indicate a direct role for astrocytes in degradation of Abeta and implicate deficits in astroglial clearance of Abeta in the pathogenesis of AD. Treatments that increase removal of Abeta by astrocytes may therefore be a critical mechanism to reduce the neurodegeneration associated with AD.
- Published
- 2003